Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-11-13

AUTHORS

Kyle M. Gardiner, Susan E. Tett, Christine E. Staatz

ABSTRACT

BACKGROUND: Globally, enteric-coated mycophenolate sodium (EC-MPS) is replacing mycophenolate mofetil (MMF) in maintenance immunosuppressant regimens. The predominant reason for conversion is the purported improvement in gastrointestinal (GI) quality of life. This paper considers the level of bias associated with studies comparing EC-MPS and MMF for GI-related improvement and provides insight into whether conversion is supported by evidence. METHODS: Using a pre-determined protocol, a literature search was conducted. Full-text review, data extraction and risk of bias analysis was conducted by two independent authors using the Cochrane domain-based evaluation of risk of bias. The review was reported according to the preferred reporting items for systematic reviews and meta-analyses. RESULTS: Twenty-nine studies were included in risk of bias analysis. Of these, only three were deemed a low risk of bias. Across these three studies, there were no statistically significant differences in the proportion of GI-related adverse events nor was there a significant difference in the GI-related quality of life between EC-MPS- and MMF-treated patients in these data. CONCLUSION: There was a high risk of bias across the 29 studies investigating conversion from MMF to EC-MPS for potential improvement in GI-related quality of life. The consolidated results of the three studies with low risk of bias suggest no evidence to convert patients stabilised on MMF. If a patient experiences GI-related adverse events whilst taking MMF, other methods should be explored before conversion to EC-MPS. More... »

PAGES

271-282

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40268-018-0254-8

DOI

http://dx.doi.org/10.1007/s40268-018-0254-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109888723

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30426342


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Tract", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mycophenolic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tablets, Enteric-Coated", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Discipline of Pharmacy, Queensland University of Technology, Gardens Point Campus, Level 9, Q Block, 2 George Street, Brisbane, QLD 4000 Australia", 
          "id": "http://www.grid.ac/institutes/grid.1024.7", 
          "name": [
            "School of Pharmacy, University of Queensland, Brisbane, QLD 4102 Australia", 
            "Discipline of Pharmacy, Queensland University of Technology, Gardens Point Campus, Level 9, Q Block, 2 George Street, Brisbane, QLD 4000 Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gardiner", 
        "givenName": "Kyle M.", 
        "id": "sg:person.0576205245.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576205245.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmacy, University of Queensland, Brisbane, QLD 4102 Australia", 
          "id": "http://www.grid.ac/institutes/grid.1003.2", 
          "name": [
            "School of Pharmacy, University of Queensland, Brisbane, QLD 4102 Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tett", 
        "givenName": "Susan E.", 
        "id": "sg:person.01172140022.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172140022.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmacy, University of Queensland, Brisbane, QLD 4102 Australia", 
          "id": "http://www.grid.ac/institutes/grid.1003.2", 
          "name": [
            "School of Pharmacy, University of Queensland, Brisbane, QLD 4102 Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Staatz", 
        "givenName": "Christine E.", 
        "id": "sg:person.01364721362.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364721362.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00002018-200124090-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025769271", 
          "https://doi.org/10.2165/00002018-200124090-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200826110-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029686341", 
          "https://doi.org/10.2165/00019053-200826110-00007"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11-13", 
    "datePublishedReg": "2018-11-13", 
    "description": "BACKGROUND: Globally, enteric-coated mycophenolate sodium (EC-MPS) is replacing mycophenolate mofetil (MMF) in maintenance immunosuppressant regimens. The predominant reason for conversion is the purported improvement in gastrointestinal (GI) quality of life. This paper considers the level of bias associated with studies comparing EC-MPS and MMF for GI-related improvement and provides insight into whether conversion is supported by evidence.\nMETHODS: Using a pre-determined protocol, a literature search was conducted. Full-text review, data extraction and risk of bias analysis was conducted by two independent authors using the Cochrane domain-based evaluation of risk of bias. The review was reported according to the preferred reporting items for systematic reviews and meta-analyses.\nRESULTS: Twenty-nine studies were included in risk of bias analysis. Of these, only three were deemed a low risk of bias. Across these three studies, there were no statistically significant differences in the proportion of GI-related adverse events nor was there a significant difference in the GI-related quality of life between EC-MPS- and MMF-treated patients in these data.\nCONCLUSION: There was a high risk of bias across the 29 studies investigating conversion from MMF to EC-MPS for potential improvement in GI-related quality of life. The consolidated results of the three studies with low risk of bias suggest no evidence to convert patients stabilised on MMF. If a patient experiences GI-related adverse events whilst taking MMF, other methods should be explored before conversion to EC-MPS.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40268-018-0254-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1020803", 
        "issn": [
          "1174-5886", 
          "1179-6901"
        ], 
        "name": "Drugs in R&D", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "enteric-coated mycophenolate sodium", 
      "mycophenolate mofetil", 
      "quality of life", 
      "Gastrointestinal Quality", 
      "adverse events", 
      "lower risk", 
      "domain-based evaluation", 
      "Preferred Reporting Items", 
      "significant differences", 
      "full-text review", 
      "pre-determined protocol", 
      "immunosuppressant regimens", 
      "mycophenolate sodium", 
      "bias analysis", 
      "high risk", 
      "Reporting Items", 
      "independent authors", 
      "systematic review", 
      "literature search", 
      "patients", 
      "data extraction", 
      "mofetil", 
      "risk", 
      "predominant reason", 
      "GI", 
      "review", 
      "regimens", 
      "study", 
      "purported improvements", 
      "life", 
      "evidence", 
      "differences", 
      "improvement", 
      "events", 
      "quality", 
      "sodium", 
      "proportion", 
      "bias", 
      "levels", 
      "evaluation", 
      "protocol", 
      "level of bias", 
      "potential improvements", 
      "analysis", 
      "search", 
      "items", 
      "data", 
      "reasons", 
      "conversion", 
      "authors", 
      "results", 
      "insights", 
      "method", 
      "consolidated results", 
      "extraction", 
      "paper", 
      "maintenance immunosuppressant regimens", 
      "Cochrane domain-based evaluation", 
      "proportion of GI", 
      "Enteric-Coated Mycophenolate Sodium Justifiable", 
      "Mycophenolate Sodium Justifiable", 
      "Sodium Justifiable", 
      "Justifiable"
    ], 
    "name": "Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?", 
    "pagination": "271-282", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109888723"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40268-018-0254-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30426342"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40268-018-0254-8", 
      "https://app.dimensions.ai/details/publication/pub.1109888723"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_771.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40268-018-0254-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0254-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0254-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0254-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0254-8'


 

This table displays all metadata directly associated to this object as RDF triples.

175 TRIPLES      22 PREDICATES      97 URIs      87 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40268-018-0254-8 schema:about N21f23dd28a194173990945d1c85df621
2 N43d255db45584f07b9f50890f908e810
3 Nd5ee28ff43d34f33bf1b41b166de23d7
4 Ne3bb63006e5047cc9a466724f5490ff5
5 Ne93150ba832a48268d3375c6f7e761ee
6 Necb26c05606f47d2bb4d55f74ec66656
7 anzsrc-for:11
8 anzsrc-for:1117
9 schema:author N1329b45562914b22952d2c8f88166106
10 schema:citation sg:pub.10.2165/00002018-200124090-00002
11 sg:pub.10.2165/00019053-200826110-00007
12 schema:datePublished 2018-11-13
13 schema:datePublishedReg 2018-11-13
14 schema:description BACKGROUND: Globally, enteric-coated mycophenolate sodium (EC-MPS) is replacing mycophenolate mofetil (MMF) in maintenance immunosuppressant regimens. The predominant reason for conversion is the purported improvement in gastrointestinal (GI) quality of life. This paper considers the level of bias associated with studies comparing EC-MPS and MMF for GI-related improvement and provides insight into whether conversion is supported by evidence. METHODS: Using a pre-determined protocol, a literature search was conducted. Full-text review, data extraction and risk of bias analysis was conducted by two independent authors using the Cochrane domain-based evaluation of risk of bias. The review was reported according to the preferred reporting items for systematic reviews and meta-analyses. RESULTS: Twenty-nine studies were included in risk of bias analysis. Of these, only three were deemed a low risk of bias. Across these three studies, there were no statistically significant differences in the proportion of GI-related adverse events nor was there a significant difference in the GI-related quality of life between EC-MPS- and MMF-treated patients in these data. CONCLUSION: There was a high risk of bias across the 29 studies investigating conversion from MMF to EC-MPS for potential improvement in GI-related quality of life. The consolidated results of the three studies with low risk of bias suggest no evidence to convert patients stabilised on MMF. If a patient experiences GI-related adverse events whilst taking MMF, other methods should be explored before conversion to EC-MPS.
15 schema:genre article
16 schema:inLanguage en
17 schema:isAccessibleForFree true
18 schema:isPartOf N5df32854254e447b8117017ab79fe066
19 Nb587a3b410184687a08bfbedca23fb52
20 sg:journal.1020803
21 schema:keywords Cochrane domain-based evaluation
22 Enteric-Coated Mycophenolate Sodium Justifiable
23 GI
24 Gastrointestinal Quality
25 Justifiable
26 Mycophenolate Sodium Justifiable
27 Preferred Reporting Items
28 Reporting Items
29 Sodium Justifiable
30 adverse events
31 analysis
32 authors
33 bias
34 bias analysis
35 consolidated results
36 conversion
37 data
38 data extraction
39 differences
40 domain-based evaluation
41 enteric-coated mycophenolate sodium
42 evaluation
43 events
44 evidence
45 extraction
46 full-text review
47 high risk
48 immunosuppressant regimens
49 improvement
50 independent authors
51 insights
52 items
53 level of bias
54 levels
55 life
56 literature search
57 lower risk
58 maintenance immunosuppressant regimens
59 method
60 mofetil
61 mycophenolate mofetil
62 mycophenolate sodium
63 paper
64 patients
65 potential improvements
66 pre-determined protocol
67 predominant reason
68 proportion
69 proportion of GI
70 protocol
71 purported improvements
72 quality
73 quality of life
74 reasons
75 regimens
76 results
77 review
78 risk
79 search
80 significant differences
81 sodium
82 study
83 systematic review
84 schema:name Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
85 schema:pagination 271-282
86 schema:productId N038bc10a1ea848c3b5a10e1300be8e9d
87 N659935c40f51462abb4c644d0d8d3b7e
88 N68553f3ccbbe4d068209b690aebb8d45
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109888723
90 https://doi.org/10.1007/s40268-018-0254-8
91 schema:sdDatePublished 2021-12-01T19:40
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher N7b69195a3a7645b0a966acccae139f8f
94 schema:url https://doi.org/10.1007/s40268-018-0254-8
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N038bc10a1ea848c3b5a10e1300be8e9d schema:name doi
99 schema:value 10.1007/s40268-018-0254-8
100 rdf:type schema:PropertyValue
101 N1329b45562914b22952d2c8f88166106 rdf:first sg:person.0576205245.25
102 rdf:rest Nf092f045f7014ceeb9aac3f62c76bfb9
103 N21f23dd28a194173990945d1c85df621 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Humans
105 rdf:type schema:DefinedTerm
106 N43d255db45584f07b9f50890f908e810 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Tablets, Enteric-Coated
108 rdf:type schema:DefinedTerm
109 N46627cd977d047e08bb88a69b729584b rdf:first sg:person.01364721362.82
110 rdf:rest rdf:nil
111 N5df32854254e447b8117017ab79fe066 schema:issueNumber 4
112 rdf:type schema:PublicationIssue
113 N659935c40f51462abb4c644d0d8d3b7e schema:name pubmed_id
114 schema:value 30426342
115 rdf:type schema:PropertyValue
116 N68553f3ccbbe4d068209b690aebb8d45 schema:name dimensions_id
117 schema:value pub.1109888723
118 rdf:type schema:PropertyValue
119 N7b69195a3a7645b0a966acccae139f8f schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 Nb587a3b410184687a08bfbedca23fb52 schema:volumeNumber 18
122 rdf:type schema:PublicationVolume
123 Nd5ee28ff43d34f33bf1b41b166de23d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Quality of Life
125 rdf:type schema:DefinedTerm
126 Ne3bb63006e5047cc9a466724f5490ff5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Gastrointestinal Tract
128 rdf:type schema:DefinedTerm
129 Ne93150ba832a48268d3375c6f7e761ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Immunosuppressive Agents
131 rdf:type schema:DefinedTerm
132 Necb26c05606f47d2bb4d55f74ec66656 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Mycophenolic Acid
134 rdf:type schema:DefinedTerm
135 Nf092f045f7014ceeb9aac3f62c76bfb9 rdf:first sg:person.01172140022.32
136 rdf:rest N46627cd977d047e08bb88a69b729584b
137 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
138 schema:name Medical and Health Sciences
139 rdf:type schema:DefinedTerm
140 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
141 schema:name Public Health and Health Services
142 rdf:type schema:DefinedTerm
143 sg:journal.1020803 schema:issn 1174-5886
144 1179-6901
145 schema:name Drugs in R&D
146 schema:publisher Springer Nature
147 rdf:type schema:Periodical
148 sg:person.01172140022.32 schema:affiliation grid-institutes:grid.1003.2
149 schema:familyName Tett
150 schema:givenName Susan E.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172140022.32
152 rdf:type schema:Person
153 sg:person.01364721362.82 schema:affiliation grid-institutes:grid.1003.2
154 schema:familyName Staatz
155 schema:givenName Christine E.
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364721362.82
157 rdf:type schema:Person
158 sg:person.0576205245.25 schema:affiliation grid-institutes:grid.1024.7
159 schema:familyName Gardiner
160 schema:givenName Kyle M.
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576205245.25
162 rdf:type schema:Person
163 sg:pub.10.2165/00002018-200124090-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025769271
164 https://doi.org/10.2165/00002018-200124090-00002
165 rdf:type schema:CreativeWork
166 sg:pub.10.2165/00019053-200826110-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029686341
167 https://doi.org/10.2165/00019053-200826110-00007
168 rdf:type schema:CreativeWork
169 grid-institutes:grid.1003.2 schema:alternateName School of Pharmacy, University of Queensland, Brisbane, QLD 4102 Australia
170 schema:name School of Pharmacy, University of Queensland, Brisbane, QLD 4102 Australia
171 rdf:type schema:Organization
172 grid-institutes:grid.1024.7 schema:alternateName Discipline of Pharmacy, Queensland University of Technology, Gardens Point Campus, Level 9, Q Block, 2 George Street, Brisbane, QLD 4000 Australia
173 schema:name Discipline of Pharmacy, Queensland University of Technology, Gardens Point Campus, Level 9, Q Block, 2 George Street, Brisbane, QLD 4000 Australia
174 School of Pharmacy, University of Queensland, Brisbane, QLD 4102 Australia
175 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...